Researchers discover Ozempic might slow aging itself

Health

Semaglutide, the active component in popular GLP-1 drugs such as Ozempic and Wegovy, might do more than reduce hunger and enhance blood glucose. A National Institutes of Health (NIH) financed research study discovered that the drug minimized a number of hazardous impacts of aging and extended life expectancy in older, healthy mice.

Scientists at the University of California, Berkeley compared semaglutide straight with calorie constraint, among the best-known interventions for extending life expectancy in lab animals. The drug replicated a number of the anti-aging results of consuming less, however in a number of crucial locations, it appeared to go even further.

The findings raise an appealing possibility: GLP-1 drugs might affect the aging procedure itself. Previously animal research studies have actually revealed that these drugs can postpone the start of numerous age-related illness. If semaglutide act upon biological systems that drive aging, that might assist describe why GLP-1 treatments have actually revealed advantages throughout such a large range of health conditions.

“Most chronic diseases are deeply rooted in the aging process. If GLP-1 agonists do indeed slow it down, then a wide range of clinical benefits is exactly what you’d expect to see,” stated Rafael de Cabo, Ph.D., a senior private investigator at the NIH’s National Institute on Aging (NIA), and author of a commentary on the brand-new research study.

Checking Semaglutide Late in Life

To see what semaglutide might do when aging was currently well in progress, a research study group led by Danica Chen, Ph.D., provided the drug to 20-month-old female mice for 3 months.

Compared to neglected mice, the animals getting semaglutide revealed much better muscle and cognitive function. Gene activity likewise exposed enhancements in a number of biological functions connected with aging, consisting of lowered swelling and less decrease in the body’s capability to fix and regrow tissue.

The life expectancy outcomes were particularly striking. In a different group treated with semaglutide till death, typical life-span was almost 100 days longer than in unattended mice.

Was Eating Less the Real Reason?

Since semaglutide decreases cravings, the scientists would like to know whether the obvious anti-aging impacts merely originated from taking in less calories.

To evaluate that concept, they straight compared semaglutide with calorie constraint. For 5 months, one group of 20-month-old female mice got semaglutide, while another was put on a 24% calorie-restricted diet plan created to match just how much the cured mice were consuming.

The 2 methods produced numerous comparable impacts, and a lot of physiological measurements stayed steady. Semaglutide stood out in numerous locations.

Mice getting the drug enhanced beyond their beginning levels in exploratory habits, spatial memory, and blood-sugar upkeep. Their metabolic rate likewise stayed mostly the same, while metabolic process slowed in the calorie-restricted animals.

Those distinctions recommend that semaglutide might be doing more than just recreating the results of consuming less.

“These differences point to the possibility that GLP-1 drugs tap into a biological pathway independent of calorie restriction. Uncovering this potential route and the benefits that may specifically stem from it is an important direction for future research into the development of longevity-enhancing interventions,” stated Chen, matching author of the research study and teacher of metabolic biology and nutrition at UC Berkeley.

Could GLP-1 Drugs Affect Human Aging?

The findings might open brand-new instructions in durability research study, however they do disappoint that Ozempic, Wegovy, or other GLP-1 drugs can extend human life-span.

Extra medical research study will be required to identify whether the impacts seen in mice equate to individuals. One example is the current post-hoc analysis of the SLIM LIVER trial, however more research studies will be required to develop whether GLP-1 drugs can meaningfully affect human aging or durability.

Chen stated future medical research studies might likewise examine these drugs in healthy older grownups. If scientists ultimately discover comparable advantages in individuals without weight problems or diabetes, the possible usages of GLP-1 treatments might widen significantly.

NIH supported this research study through NIA grants R01AG063404, R01AG063389, and R01AG082105.